June 14, 2021 5:22pm

The cell and gene therapy sector closed positive again – 7 in a row and 8 of 10 in the June sessions

Pre-open indications: 9 HITs and 4 MISS

My comments try to distinguish the temporary from real pricing digression or progress.

If you’re looking for sector intel, ideas and facts or numbers (which don’t lie) in a volatile climate, RMi defines the rigors of share pricing! My comments distinguish the temporary from real pricing digression or progress.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  


The Dow closed DOWN -85.85 points (-0.25%); the S&P closed UP +7.71 points (+0.18%) while the Nasdaq closed UP +104.72 points (+0.74%)

 

Henry’omics:

Indexes moved mixed (the Dow slipped) as they head into a week with a key Federal Reserve meeting.

The Nasdaq jumped to a record high on Monday after last week’s outperformance with a gain of nearly 1.9%, posting its fourth winning week in a row.

I’m getting nervous new and newer and newest high force me to initiate a BYE to a percentage of my individual holdings.

An on-target quote,” The broad market’s modest performance is pretty much in line with historical patterns— specifically, June’s tendency for generally quiet trading. As the market continues to sort through potential moves made by the Fed and looming inflation, we could continue to see this narrative play out in the short-term.” <Chris Larkin, managing director of trading at E-Trade Financial>

 

RegMed Investors’ (RMi) pre-open: “The ups of the cell and gene therapy stocks has an impact on the direction of the sector. Do we foresee another rotation?” … https://www.regmedinvestors.com/articles/11953

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Monday opened positive at 26/7, 1 flat and 1 acquired, stayed positive at the mid-day to 19/14, 2 flats and 1 acquired, closing positive at 18/14, 2 flats and 1 acquired;

 

The Biostage (BSTG) Chronicles: The “pump” is not promoting share pricing on Monday with 2,305 shares traded and NO gain after Friday’s 1,395 shares traded moving up +$0.04 to $1.25, Thursday’s 1,050 share traded only moved the share price +$0.01 to $1.21, Wednesday’s 2,200 shares traded with a negative close of -$0.06 to $1.20, Tuesday’s 1,216 shares traded i.e., were “pumped” as the stock increased +0.13 to $1.26 and last Monday’s 2,350 shares traded dropping the stock -$0.17 to $1.13, WHO is buying this “zombie”?

 

Pre-open Indications: 8 HITs < Biostage (BSTG -$0.00), Cellectis SA (CLL +$0.62), Ultragenyx (RARE +$1.17), Vericel (VCEL +$0.19), Precigen (PRGN -$0.28), Global Blood Therapeutics (GBT -$0.36), Mesoblast (MESO -$0.11) and 3 MISS < Voyager Therapeutics (VYGR -$0.04), BioLife Solutions (BLFS +$0.63), Pluristem (PSTI -$0.02)>

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … MESO added: https://www.regmedinvestors.com/articles/11628

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Intellia Therapeutics (NTLA), Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP), ReNeuron (RENE.L.), Ultragenyx (RARE) to name 5 of the 18 inclining of the 35 covered

Hammered in today’s market:

  • Sage Therapeutics (SAGE), uniQure NV (QURE), bluebird bio (BLUE), Global Blood therapeutics (GBT), Regenxbio (RGNX) to name 5 of the 14 declining of the 35 covered

 

Key metrics:

  • Sector volume was LOW with 4 of the 18-upside having higher than the 3-month average volume with the volume of 5 of 14-downside having higher than the 3-month average volume;
  • Monday’s percentage (%) of the 18-upside were +0.25% (FATE) to +5.11% (VSTM) while the 14-downside ranges from –0.09% (SGMO) to -7.90% (SAGE);

 

Monday’s (10 of 18) incliners:

  • Intellia Therapeutics (NTLA +$2.71 after Friday’s +$2.14);
  • CRISPR Therapeutics (CRSP +$1.76 after Friday's +$3.29);
  • Alnylam Pharmaceuticals (ALNY +$1.64 after Friday’s +$1.76);
  • Ultragenyx (RARE +$1.17 after Friday’s +$2.35);
  • Editas medicine (EDIT +$1.11);
  • ReNeuron (REN.L +$1.00 after Friday’s +$8.00);
  • BioLife Solutions (BLFS +$0.63 after Friday’s +$1.13);
  • Cellectis SA (CLLS +$0.62 after Friday’s -$0.12);
  • Verastem (VSTM (+$0.23)
  • Fate therapeutics (FATE+$0.22 after Friday’s FATE +$1.33);
  • AxoGen (AXGN +$0.22 after Friday’s +$0.87)  

Monday’s (12 of 14) decliners:

  • Sage Therapeutics (SAGE +$6.25 after Friday’s +$3.02);
  • uniQure NV (QURE -$2.17 after Friday’s -$0.60);
  • bluebird bio (BLUE -$0.57);
  • Global Blood Therapeutics (GBT -$0.36 after Friday’s -$1.03);
  • Precigen (PGEN -$0.28);
  • Regenxbio (RGNX -$0.16 after Friday’s -$0.09);
  • Ionis Pharmaceuticals (IONS -$0.14 after Friday’s -$0.28);
  • Mesoblast (MESO -$0.11);
  • Athersys (ATHX -$0.05);
  • Adverum Biotechnologies (ADVM -$0.04);

Closing flat - 2 - Solid Biosciences (SLDB) Biostage (BSTG) and 1 -Stemline Therapeutics (STML – acquired)

 

COVID-19 updates:

More than half of Americans have received at least one dose of a vaccine and 42% are fully vaccinated.

Friday’s COVID Data Tracker <Million>:

  • Cases: 34,324 M 
  • Death rate totaled 615,119 M
  • Recovered/Discharged 28,417,775

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB closed down -0.17% and XBI closed up +0.63%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was up +0.74 points or4.73% at 16.38

Upside volume: weak

  • Monday: 4 out of the 18-upside had higher than the 3-month average volume;

Downside volume: low

  • Monday: 5 out of the 14-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: price versus percentage …

Monday’s percentage (%) of the 18-upside were +0.25% (FATE) to +5.11% (VSTM) while the 14-downside ranges from –0.09% (SGMO) to -7.90% (SAGE);

 

June, third month of Q2/21:

Monday closed positive with 18 advancers, 14 decliners, 2 flats and 1 acquired

 

The BOTTOM LINE: Eight (8) of ten (10) positive sector closes in June … that includes seven (7) in a row

it's still a tricky market, don’t be ‘suckered” by the new of newest highs.

I’m in for the “ride” however, I’m STIL expecting the sector rotation trades to continue to play out – I’m maintaining SELLING into STRENGTH into Friday.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

Don’t get complacent …

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.